Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of oral omadacycline as compared to placebo in the treatment of adults with Nontuberculous Mycobacterial (NTM) pulmonary disease caused by Mycobacterium abscessus complex (MABc)


Clinical Trial Description

The total duration of subject participation in the study is approximately 5 months which includes a total duration of study treatment for approximately 3 months (84 days). Eligible participants will be randomized 1.5:1 to receive 3 months of treatment with either omadacycline or placebo (monotherapy). The study will use a double-dummy design in order to maintain the study blinding. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04922554
Study type Interventional
Source Paratek Pharmaceuticals Inc
Contact
Status Active, not recruiting
Phase Phase 2
Start date October 15, 2021
Completion date July 2024

See also
  Status Clinical Trial Phase
Completed NCT03038178 - Liposomal Amikacin for Inhalation (LAI) in the Treatment of Mycobacterium Abscessus Lung Disease Phase 2
Terminated NCT04154826 - Recombinant Interleukin-7 (CYT107) to Treat Patients With Refractory Nontuberculous Mycobacterial Lung Disease Phase 2
Completed NCT02344004 - Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone Phase 3
Recruiting NCT02355015 - A Prospective Registry For Non Tuberculous Mycobacterial (NTM) Infections N/A
Completed NCT03421743 - Pilot Trial of Inhaled Molgramostim in Nontuberculous Mycobacterial (NTM) Infection Phase 2
Terminated NCT03597347 - Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection Phase 2
Completed NCT02832843 - Genome-Wide Association Study in Patients With Nontuberculous Mycobacterial Lung Disease
Recruiting NCT06266442 - M. Avium WGS During Mav-PD Treatment
Completed NCT04677543 - Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex Phase 3
Completed NCT02340897 - Diagnostic Accuracy of Nontuberculous Mycobacterial Lung Disease Based on Chest CT N/A
Completed NCT01315236 - Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria Phase 2
Recruiting NCT04677569 - Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex Phase 3